The role of treatment to increase HDL‐cholesterol and decrease triglyceride concentrations in prevention of coronary heart disease in Type 2 diabetes

Byrne, Christopher D.

doi:10.1111/j.1464-5491.2004.1424-5.x

Cited by 10 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition to the dietary restriction of fat and normalization of glycemia in patients with T2DM, medications that lower TGs and raise the HDL-C include statins, fibrates, niacin, some omega-3 fatty acid preparations, thiazolidinediones and more recently GLP-1 agonists. [174][175][176][177][178][179] The recommendation to help patients lose weight, although universally endorsed, is infrequently followed by the formal implementation of a weight management program with pharmacological intervention.…”

Section: Bariatric Endocrinology and The Management Of Adiposopathymentioning

confidence: 99%

Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association

Bays

Tóth

Kris-Etherton

et al. 2013

Journal of Clinical Lipidology

404

280

View full text Add to dashboard Cite

The term "fat" may refer to lipids as well as the cells and tissue that store lipid (ie, adipocytes and adipose tissue). "Lipid" is derived from "lipos," which refers to animal fat or vegetable oil. Adiposity refers to body fat and is derived from "adipo," referring to fat. Adipocytes and adipose tissue store the greatest amount of body lipids, including triglycerides and free cholesterol. Adipocytes and adipose tissue are active from an endocrine and immune standpoint. Adipocyte hypertrophy and excessive adipose tissue accumulation can promote pathogenic adipocyte and adipose tissue effects (adiposopathy), resulting in abnormal levels of circulating lipids, with dyslipidemia being a major atherosclerotic coronary heart disease risk factor. It is therefore incumbent upon lipidologists to be among the most knowledgeable in the understanding of the relationship between excessive body fat and dyslipidemia. On September 16, 2012, the National Lipid Association held a Consensus Conference with the goal of better defining the effect of adiposity on lipoproteins, how the pathos of excessive body fat (adiposopathy) contributes to dyslipidemia, and how therapies such as appropriate nutrition, increased physical activity, weight-management drugs, and bariatric surgery might be expected to impact dyslipidemia. It is hoped that the information derived from these proceedings will promote a greater appreciation among clinicians of the impact of excess adiposity and its treatment on dyslipidemia and prompt more research on the effects of interventions for improving dyslipidemia and reducing cardiovascular disease risk in overweight and obese patients.

show abstract

Section: Bariatric Endocrinology and The Management Of Adiposopathymentioning

confidence: 99%

Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association

Bays

Tóth

Kris-Etherton

et al. 2013

Journal of Clinical Lipidology

404

280

View full text Add to dashboard Cite

show abstract

“…Dyslipidaemia is an important risk factor for CVD in type 2 diabetes 33 and this has been highlighted in the NICE guidelines. 23 The typical profile of dyslipidaemia in type 2 diabetes is decreased HDL-C and elevated TG, 34 which are both risk factors for coronary heart disease. 35 Several studies suggest that pioglitazone has a more favourable effect than rosiglitazone on HDL-C and TG and two meta-analyses 36,37 support this suggestion.…”

Section: Dyslipidaemiamentioning

confidence: 99%

The role of metformin and pioglitazone in early combination treatment of type 2 diabetes mellitus

Campbell¹

2006

Diabetes & Vascular Disease

View full text Add to dashboard Cite

Metformin will celebrate 50 years of clinical use in 2007. Pioglitazone was introduced into clinical practice in 1999. Both metformin and pioglitazone have positive effects on components of the metabolic syndrome, namely: insulin resistance, hyperinsulinaemia, visceral obesity, hyperglycaemia, dyslipidaemia and hypertension and risk factors involved in endothelial dysfunction, inflammation and atherosclerosis. Improvements in cardiovascular outcomes have been demonstrated in patients at high risk of macrovascular events with pioglitazone (PROactive) and in overweight patients with metformin (UKPDS 34). Pioglitazone may also help to sustain beta-cell function. Introduction of combination therapy using two differently acting oral antidiabetic agents at the time of diagnosis or early thereafter is becoming increasingly common in order to reach glycaemic targets (e.g. HbA1C ≤7.0%). The combination of metformin and pioglitazone in an early stage of type 2 diabetes enables greater likelihood that these targets can be with insulin secretagogues. attained without the risk of hypoglycaemia associated with insulin secretagogues

show abstract

“…Hypertriglyceridemia is a common feature of T2DM, characterized by decreased clearance of triglyceride-rich lipoprotein, due to a reduction in the levels of lipoprotein lipase or alterations in circulating lipoproteins [49]. Elevated triglyceride levels correlate with the severity of atherosclerosis and coronary heart disease in diabetic patients [50]. FFA levels are also elevated in T2DM, which may shed light on the mechanistic relationship between increased fat, insulin resistance, impaired glucose tolerance and central obesity [49].…”

Section: Diabetesmentioning

confidence: 99%

Cardiovascular Complications in Diabetes

Chagas¹

2014

J Diabetes Metab

View full text Add to dashboard Cite

Cardiovascular disease is the primary cause of morbidity and mortality among the diabetic population. Diabetic cardiomyopathy is characterized by early impairments in diastolic function, accompanied by the development of cardiomyocyte hypertrophy, myocardial fibrosis and cardiomyocyte apoptosis. The pathophysiology underlying diabetes-induced cardiac damage is complex and multifactorial, with elevated oxidative stress as a key contributor. The current evidence of molecular disturbances present in the diabetic heart, and their role in the development of diabetes-induced impairments in myocardial function and structure. This review aims to address the recent aspects of the relationships between diabetic cardiomyopathy and cardiovascular disease. J ou rna l o f D ia be tes & M e ta bolism

show abstract

The role of treatment to increase HDL‐cholesterol and decrease triglyceride concentrations in prevention of coronary heart disease in Type 2 diabetes

Cited by 10 publications

References 21 publications

Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association

Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association

The role of metformin and pioglitazone in early combination treatment of type 2 diabetes mellitus

Cardiovascular Complications in Diabetes

Contact Info

Product

Resources

About